41 results
424B3
INM
InMed Pharmaceuticals Inc
6 Jul 22
Prospectus supplement
2:43pm
could delay or prevent commercialization and result in materially adverse effects on our business.
The COVID-19 coronavirus pandemic could adversely … Conduct as well as our corporate disclosure, insider trading and whistle blower policies.
In response to the COVID-19 pandemic, commencing in March 2020
424B5
nwyf2
3 Jun 22
Prospectus supplement for primary offering
9:45pm
424B3
7zlcccog
25 Apr 22
Prospectus supplement
5:02pm
424B3
3bh274da8x37
7 Apr 22
Prospectus supplement
4:46pm
S-3
27i2qo4 fcv
4 Feb 22
Shelf registration
4:36pm
8-K
EX-99.1
55sp p7nihiojzw7
5 Jan 22
InMed Issues Annual Letter to Shareholders Highlighting Key Accomplishments from 2021 and Providing 2022 Outlook
2:22pm
8-K/A
EX-99.1
xkafv4mdiwix l9o7
22 Dec 21
Audited Financial Statements
12:00am
8-K/A
EX-99.2
eketjh9niu8i
22 Dec 21
Audited Financial Statements
12:00am
8-K
EX-2.1
fx8k j78tuetj
13 Oct 21
InMed Pharmaceuticals Completes Acquisition of BayMedica Creating a Market Leader in the Manufacturing of Rare Cannabinoids
5:00pm